ProCE Banner Activity

DRIVE-FORWARD and DRIVE-AHEAD: Safety and Efficacy of Doravirine in Treatment-Naive Adults at 4 Yr

Slideset Download
Conference Coverage
In combined analysis of open-label extension, maintenance of virologic suppression was demonstrated through 192 weeks.

Released: November 03, 2021

Expiration: November 02, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.

ViiV Healthcare